Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative

American Journal of Surgical Pathology

Volumn 32, Issue 9, 2008, Pages 1421-1426

  Kadin, Marshall E ^a,b,d,h   Pinkus, Jack L ^b   Pinkus, Geraldine S ^a,b   Duran, Ivan H ^c   Fuller, Christine E ^e   Onciu, Mihaela ^f   Kawaguchi, Hiroyuki ^f,g   Morris, Stephan W ^f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c St Anne's Hospital   (United States)

^d Roger William Medical Center   (United States)

^e State University of New York Upstate Medical University: College of Medicine   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g TOKYO DENTAL COLLEGE   (Japan)

^h ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

ALK; Anaplastic large cell lymphoma; Cutaneous

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; MUCIN 1; NUCLEOPHOSMIN; CA 15-3 ANTIGEN; CTAGE1 PROTEIN, HUMAN; MEMBRANE PROTEIN; PROTEIN TYROSINE KINASE; TUMOR ANTIGEN;

ADULT; ANAMNESIS; ANAPLASTIC CARCINOMA; ARTICLE; CASE REPORT; CELL INFILTRATION; CHROMOSOME 2; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 2; CYTOPLASM; EPITHELIUM HYPERPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE LOCUS; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPH FLOW; MALE; MULTINUCLEAR CELL; PHENOTYPE; PRIMARY TUMOR; SKIN BIOPSY; SKIN TUMOR; TUMOR CELL; TUMOR RECURRENCE; AGED; ANAPLASTIC LARGE CELL LYMPHOMA; BIOSYNTHESIS; ENZYME ACTIVATION; GENETICS; METABOLISM; MIDDLE AGED; ONSET AGE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGE OF ONSET; AGED; ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; ENZYME ACTIVATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

EID: 52149115595     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181648d6d     Document Type: Article

References (23)

1. Aoki M, Niimi Y, Takezaki S, et al. CD30+lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. Br J Dermatol. 2001;145: 123-212.
2. Bekkenk MW, Geelen FA, Voorst VPC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.
3. Beylot-Berry M, Lamant L, Vergier B, et al. Detection of t(2;5)(p23;q35) translocation by reverse transcription polymerase reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol. 1996;149:483-492.
4. Courville P, Wechsler J, Thomine E, et al. Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopatho-logical and immunohistochemical study with particular interest in epithelial growth factor expression. The French Study Group on Cutaneous Lymphoma. Br J Dermatol. 1999;140:421-426.
5. De Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127-135.
6. DeCoteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87: 3437-3441.
7. Fuller CE, Wang H, Zhang W, et al. High-throughput molecular profiling of high-grade astrocytomas: the utility of fluorescence in situ hybridization on tissue microarrays (TMA-FISH). J Neuropathol Exp Neurol. 2002;61:1078-1084.
8. Hernandez L, Pinyol M, Hernandez S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood. 1999;94:3265-3268.
9. Horie R, Watanabe M, Ishida T, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma. Cancer Cell. 2004;5:353-364.
10. Hutchison RE, Banki K, Shuster JJ, et al. Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol. 1997;8(suppl 1):37-42.
11. Kadin ME. The spectrum of Ki-1+ cutaneous lymphomas. Curr Probl Dermatol. 1990;19:132-143.
12. Kempf W, Willemze R, Jaffe ES, et al. CD30+T-cell lymphoproliferative disorders. In: Leboit PE, Burg G, Weedon D, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Skin Tumours. Lyon: IARC Press; 2006:179-181.
13. Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30+ALCL. Report of 27 cases. J Cutan Pathol. 1993;20:193-202.
14. Li R, Morris SW. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev. 2007 [Epub ahead of print].
15. Megonigal MD, Rappaport EF, Wilson RB, et al. Panhandle PCR for cDNA: a rapid method for isolation of MLL fusion transcripts involving unknown partner genes. Proc Natl Acad Sci USA. 2000; 97:9597-9602.
16. + hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007;128:445-453.
17. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol. 2004;199: 330-358.
18. Sasaki K, Sugaya M, Fujita H, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol. 2004;150:1202-1207.
19. +lymphoproliferative disorders. J Cutan Pathol. 1997;24:597-603.
20. ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partially glycosylated form. J Clin Pathol. 2001;54:933-939.
21. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALKpositive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood. 2000;95:3204-3207.
22. Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (ALK) fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res. 2000;60: 793-798.
23. +cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol. 1998;22:1192-1202.